Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Adult
Aged
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents, Immunological
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
/ analysis
Cohort Studies
Disease Progression
Female
Humans
Imidazoles
/ administration & dosage
Immune Checkpoint Inhibitors
/ administration & dosage
MAP Kinase Kinase Kinases
/ antagonists & inhibitors
Male
Melanoma
/ drug therapy
Middle Aged
Mutation, Missense
Neoplasm Metastasis
Oximes
/ administration & dosage
Protein Kinase Inhibitors
/ administration & dosage
Proto-Oncogene Proteins B-raf
/ antagonists & inhibitors
Pyridones
/ administration & dosage
Pyrimidinones
/ administration & dosage
Skin Neoplasms
/ drug therapy
Treatment Outcome
Young Adult
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
13
04
2020
accepted:
26
08
2020
pubmed:
7
10
2020
medline:
15
12
2020
entrez:
6
10
2020
Statut:
ppublish
Résumé
Immune and targeted therapies achieve long-term survival in metastatic melanoma; however, new treatment strategies are needed to improve patients' outcomes
Identifiants
pubmed: 33020648
doi: 10.1038/s41591-020-1082-2
pii: 10.1038/s41591-020-1082-2
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Imidazoles
0
Immune Checkpoint Inhibitors
0
Oximes
0
Protein Kinase Inhibitors
0
Pyridones
0
Pyrimidinones
0
trametinib
33E86K87QN
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
MAP Kinase Kinase Kinases
EC 2.7.11.25
dabrafenib
QGP4HA4G1B
spartalizumab
QOG25L6Z8Z
Banques de données
ClinicalTrials.gov
['NCT02967692']
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1557-1563Références
Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 20, 1239–1251 (2019).
pubmed: 31345627
doi: 10.1016/S1470-2045(19)30388-2
Robert, C. et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N. Engl. J. Med. 381, 626–636 (2019).
pubmed: 31166680
doi: 10.1056/NEJMoa1904059
Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
pubmed: 31562797
doi: 10.1056/NEJMoa1910836
McArthur, G. et al. 5-Year survival update of cobimetinib plus vemurafenib in BRAF V600 mutation-positive advanced melanoma: final analysis of the coBRIM study. Pigment Cell Melanoma Res. 33, 148–255 (2020).
doi: 10.1111/pcmr.12834
Ugurel, S. et al. Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition – update 2019. Eur. J. Cancer 130, 126–138 (2020).
pubmed: 32179447
doi: 10.1016/j.ejca.2020.02.021
Ugurel, S. et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies – update 2017. Eur. J. Cancer 83, 247–257 (2017).
pubmed: 28756137
doi: 10.1016/j.ejca.2017.06.028
Hu-Lieskovan, S. et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med. 7, 279ra241 (2015).
doi: 10.1126/scitranslmed.aaa4691
Kakavand, H. et al. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients. Clin. Cancer Res. 21, 3140–3148 (2015).
pubmed: 25609064
doi: 10.1158/1078-0432.CCR-14-2023
Wilmott, J. S. et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18, 1386–1394 (2012).
pubmed: 22156613
doi: 10.1158/1078-0432.CCR-11-2479
Wilmott, J. S. et al. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. J. Immunol. 192, 2505–2513 (2014).
pubmed: 24489105
doi: 10.4049/jimmunol.1302616
Ascierto, P. A. & Dummer, R. Immunological effects of BRAF + MEK inhibition. Oncoimmunology 7, e1468955 (2018).
pubmed: 30228935
pmcid: 6140547
doi: 10.1080/2162402X.2018.1468955
Mandalà, M. et al. Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. Lab. Invest. 97, 166–175 (2017).
pubmed: 27991907
doi: 10.1038/labinvest.2016.132
Yu, C. et al. Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma. Front. Immunol. 10, 990 (2019).
pubmed: 31134073
pmcid: 6513976
doi: 10.3389/fimmu.2019.00990
Kelderman, S., Schumacher, T. N. & Haanen, J. B. Acquired and intrinsic resistance in cancer immunotherapy. Mol. Oncol. 8, 1132–1139 (2014).
pubmed: 25106088
pmcid: 5528612
doi: 10.1016/j.molonc.2014.07.011
Ascierto, P. A. et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur. J. Cancer 126, 33–44 (2020).
pubmed: 31901705
doi: 10.1016/j.ejca.2019.11.016
Ascierto, P. A. et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat. Med. 25, 941–946 (2019).
doi: 10.1038/s41591-019-0448-9
pubmed: 31171878
Ribas, A. et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat. Med. 25, 936–940 (2019).
pubmed: 31171879
doi: 10.1038/s41591-019-0476-5
pmcid: 8562134
Sullivan, R. J. et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat. Med. 25, 929–935 (2019).
pubmed: 31171876
doi: 10.1038/s41591-019-0474-7
Ferrucci, P. F. et al. Updated survival in patients with BRAF-mutant melanoma administered pemobrlizumab, dabrafenib, and trametinib. Pigment Cell Melanoma Res. 33, 148–255 (2020).
doi: 10.1111/pcmr.12834
McArthur, G. A. et al. Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAF
Lin, C.-C. et al. Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. Ann. Oncol. 29, VIII413 (2018).
doi: 10.1093/annonc/mdy288.032
Larkin, J. et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J. Clin. Oncol. 36, 383–390 (2018).
pubmed: 28671856
doi: 10.1200/JCO.2016.71.8023
Hamid, O. et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur. J. Cancer 86, 37–45 (2017).
pubmed: 28961465
doi: 10.1016/j.ejca.2017.07.022
Ribas, A. et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16, 908–918 (2015).
pubmed: 26115796
doi: 10.1016/S1470-2045(15)00083-2
pmcid: 9004487
Wagle, M. C. et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis. Oncol. 2, 7 (2018).
pubmed: 29872725
pmcid: 5871852
doi: 10.1038/s41698-018-0051-4
Long, G. V. et al. Characteristics of long-term survivors and subgroup analyses with combination nivolumab plus ipilimumab for advanced melanoma (CheckMate 067). Pigment Cell Melanoma Res. 33, 148–255 (2020).
doi: 10.1111/pcmr.12834
Osgood, C. et al. FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable metastatic melanoma (UMM) by therapy type. J. Clin. Oncol. 37, 9508 (2019).
doi: 10.1200/JCO.2019.37.15_suppl.9508
Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).
pubmed: 30309915
pmcid: 6718162
doi: 10.1126/science.aar3593
Hodi, F. S. et al. Genomic analyses and immunotherapy in advanced melanoma. Cancer Res. 79, CT037 (2019).
Ribas, A. et al. Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study. Cancer Res. 79, 4217 (2019).
Weber, J. S. et al. Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial. Ann. Oncol. 30, V533–V534 (2019).
Dummer, R. et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 21, 358–372 (2020).
pubmed: 32007138
doi: 10.1016/S1470-2045(20)30062-0
Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer Cell 35, 238–255 (2019).
pubmed: 30753825
doi: 10.1016/j.ccell.2019.01.003
Vilain, R. E. et al. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin. Cancer Res. 23, 5024–5033 (2017).
pubmed: 28512174
doi: 10.1158/1078-0432.CCR-16-0698
Massi, D. et al. The density and spatial tissue distribution of CD8(
pubmed: 31730502
pmcid: 6858711
doi: 10.1186/s40425-019-0797-4
Lee, J. H. et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann. Oncol. 28, 1130–1136 (2017).
pubmed: 28327969
doi: 10.1093/annonc/mdx026
Santiago-Walker, A. et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin. Cancer Res. 22, 567–574 (2016).
pubmed: 26446943
doi: 10.1158/1078-0432.CCR-15-0321
Riester, M. et al. PureCN: copy number calling and SNV classification using targeted short read sequencing. Source Code Biol. Med. 11, 13 (2016).
pubmed: 27999612
pmcid: 5157099
doi: 10.1186/s13029-016-0060-z
Oh, S. et al. Reliable analysis of clinical tumor-only whole-exome sequencing data. JCO Clin. Cancer Inf. 4, 321–335 (2020).
Atkinson, V. et al. Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists. Asia Pac. J. Clin. Oncol. 12, 5–12 (2016).
pubmed: 27905182
doi: 10.1111/ajco.12656
Menzies, A. M. et al. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann. Oncol. 26, 415–421 (2015).
pubmed: 25411413
doi: 10.1093/annonc/mdu529
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
pubmed: 19451168
pmcid: 2705234
doi: 10.1093/bioinformatics/btp324
McKenna, A. et al. The genome analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
pubmed: 20644199
pmcid: 2928508
doi: 10.1101/gr.107524.110
DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).
pubmed: 21478889
pmcid: 3083463
doi: 10.1038/ng.806
Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
pubmed: 23396013
pmcid: 3833702
doi: 10.1038/nbt.2514
Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865–2871 (2009).
pubmed: 19561018
pmcid: 2781750
doi: 10.1093/bioinformatics/btp394
Schroder, J. et al. Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads. Bioinformatics 30, 1064–1072 (2014).
pubmed: 24389656
pmcid: 3982158
doi: 10.1093/bioinformatics/btt767
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886
Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
doi: 10.1093/bioinformatics/btu638
pubmed: 25260700
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
doi: 10.1093/bioinformatics/btp616
pubmed: 19910308
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
doi: 10.1073/pnas.0506580102
pubmed: 16199517
pmcid: 1239896
Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021
pmcid: 4707969
doi: 10.1016/j.cels.2015.12.004
Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011).
pubmed: 21546393
pmcid: 3106198
doi: 10.1093/bioinformatics/btr260
Daud, A. I. et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J. Clin. Oncol. 34, 4102–4109 (2016).
pubmed: 27863197
pmcid: 5562434
doi: 10.1200/JCO.2016.67.2477